CLINICAL RESULTS OF PATIENTS WITH FUCHS ENDOTHELIAL CORNEAL DYSTROPHY TREATMENT WITH HEMI-DESCEMET’S MEMBRANE ENDOTHELIAL KERATOPLASTY

Published 2022 - 26th ESCRS Winter Meeting

Reference: P156 | Type: Abstracts | DOI: 10.82333/jsjj-n064

Authors: Aslan Geliastanov* ¹ , Olga Antonova ¹ , Boris Malyugin ²

¹Ophthalmology,S. Fyodorov Eye Microsurgery Federal State Institution,Москва,Russian Federation, ²Ophthalmology,A.I. Yevdokimov Moscow State University Of Medicine and Dentistry,Moscow,Russian Federation;Ophthalmology,S. Fyodorov Eye Microsurgery Federal State Institution,Moscow,Russian Federation

Purpose

To report the 1-year clinical outcomes of using a semicircular Descemet membrane graft (hemi-DMEK) performed for Fuchs endothelial corneal dystrophy (FECD).

Setting

S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Methods

Prospective, interventional case series assessing the outcomes of 24 eyes from 24 patients who underwent hemi-DMEK combined with phacoemulsification and IOL implantation for FECD. Best-corrected visual acuity (BCVA), endothelial cell density (ECD) and central corneal thickness (CCT) were measured prior to surgery and up to 12 months after the procedure.

Results

Hemi-DMEK was successful in 23 out of 24 eyes; one eye required repeated keratoplasty. BCVA improved in all successful hemi-DMEK cases: at 12 months 86 % of eye (n=20) reached = 0.5, 47% (n=11) = 0.8 and 26% (n=6) reached = 1.0. Compared to preoperative measurements, mean ECD decreased from 2850(±84) cell/mm²preoperatively to 1285±277 cell/mm²(n=20) at 1 year. Average CCT decreased from preoperative 650±44 um to 519±43 um (n=20) at 1 year postoperatively.

Conclusion

Hemi-DMEK provide favorable visual outcomes comparable to those achieved by standard DMEK. The graft survival rate complication profile turn out to be similar to standard DMEK. Hemi-DMEK might be a good option to treat patients with tep endothelial pathology, and having a potential to increase the availability of donor tissue for endothelial keratoplasty (one cornea for 2 patients).